Detected ·
Soufflé Therapeutics
$135M—
Soufflé Therapeutics announced an oversubscribed $135M Series B financing led by Juvia Group, with participation from TCGX, BB Biotech, Fidelity Investments, Amgen, ARCH Venture Partners, Bessemer Venture Partners, and others, to advance its REMEDY™ cell-specific delivery platform and pipeline programs in FSHD, heart failure, and metabolic disorders.
- Website
- —
- —
- Amount
- $135 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-10-14 04:07:48 UTC
- Signal ID
- 783827b1-0b0e-4567-896f-d3edbc99ed27
As the API returns it
{
"id": "783827b1-0b0e-4567-896f-d3edbc99ed27",
"created_at": "2026-10-14T04:07:48.931394Z",
"company_name": "Soufflé Therapeutics",
"company_website_url": null,
"company_linkedin_url": null,
"event_type": "funding",
"funding_amount": 135000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Soufflé Therapeutics announced an oversubscribed $135M Series B financing led by Juvia Group, with participation from TCGX, BB Biotech, Fidelity Investments, Amgen, ARCH Venture Partners, Bessemer Venture Partners, and others, to advance its REMEDY™ cell-specific delivery platform and pipeline programs in FSHD, heart failure, and metabolic disorders.*"
}